Pentavalent vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ImmunogenicityDiphtheria

98 competitors in Immunogenicity

#DrugCompanyPhaseTrials

1

Perjeta

Roche

Phase 3

22

Rabies Vaccine

Novartis

Phase 3

123

Prolia

OOrganon and Co

Phase 3

24

Rsvpref

Pfizer

Phase 3

55

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

36

PCV21

Sanofi

Phase 3

27

Bexsero

GSK

Phase 3

88

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

29

Opfolda

Johnson & Johnson

Phase 3

110

Gardasil

Merck & Co.

Phase 3

7Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Diphtheria2 trials

A Prospective, Multi-national, Multi-center, Open-label, Randomized, Active Controlled, Parallel Group, Operationally Seamless Phase II/III Clinical Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus (Inactivated)-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, Compared to Co-administration of DTwP-HepB-Hib Vaccine and IPV Vaccine in Healthy Infants at 6-, 10-, and 14-week of Age as Primary Series

Active, not recruiting·LLG Chem·Preclinical·NCT06947499·1,186 enrolled

A Prospective, Multi-national, Multi-center, Open-label, Randomized, Active-controlled, Parallel-group, Operationally Seamless Phase 2/3 Clinical Study to Evaluate the Immunogenicity and Safety of LBVD, a Fully Liquid Hexavalent Diphtheria-Tetanus-Whole Cell Pertussis-Hepatitis B-poliomyelitis (Inactivated)-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, Given to Healthy Infants at 6-, 10-, and 14-week of Age as Primary Series

Completed·LLG Chem·Preclinical·NCT05457946·60 enrolled

Immunogenicity1 trial

Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)

Not yet recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 4·NCT06748612·1,190 enrolled

Infections1 trial

A Phase IIa Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, in Africa

Completed·GSK·Phase 2·NCT06213506·183 enrolled

Details

Drug Info

Related News